Loading, Please Wait...
- Firdapse ® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million
-Third Quarter GAAP Net Income of $13.6 Million
-Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of $135 Million to $155 Million for FY 2020
-Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow
CORAL GABLES, Fla., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.
“We are pleased with the continued strength of our commercial launch for Firdapse® in adult LEMS patients and are very encouraged by the feedback we have received from LEMS patients, including high levels of satisfaction regarding their treatment journey through Catalyst Pathways™, our patient assistance program,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “While the U.S. launch of Firdapse remains our primary focus, we have made significant progress on our other strategic priorities. These include our recent filing of a New Drug Submission (NDS) for Firdapse with Health Canada, for which we have been granted a Priority Review. In addition, we recently met with Japanese regulatory authorities about registration requirements to obtain approval of Firdapse for Japan. Our team has done an excellent job in executing our business plan this year, and we are on track to meet all of our goals and objectives for 2019 as we move into the new year.”
Q3-19 Financial Results
Recent Developments and Highlights
For the quarter ended September 30, 2019, Catalyst reported net income of $13,630,179, or $0.13 per basic and diluted share, compared to a net loss of $7,838,873, or $0.08 per basic and diluted share, for the same period in 2018. For the nine months ended September 30, 2019, Catalyst reported net income of $23,945,624, or $0.23 per basic and diluted share, as compared to a net loss of $19,503,905, or $0.19 per basic and diluted share, for the same period in 2018.
Catalyst launched its first product, Firdapse, in January 2019. Product revenue, net for the quarter and nine months ended September 30, 2019 were $30,897,444 and $72,183,782, respectively. Cost of sales for the quarter and nine months ended September 30, 2019 were $4,387,461 and $10,360,874, respectively.
Research and development expenses for the third quarter of 2019 were $4,597,039 as compared to $4,538,369 in the third quarter of 2018. For the nine months ended September 30, 2019, research and development expenses were $12,534,362 as compared to $11,502,235 in the same period in 2018. Research and development expenses for the three and nine months ended September 30, 2019 primarily consisted of expenses for medical and regulatory affairs and quality assurance programs, as well as expenses from our ongoing clinical trials and studies evaluating Firdapse for the treatment of other ultra-orphan neuromuscular diseases and our Expanded Access Program. Research and development expenses in the comparable period in 2018, primarily consisted of consulting expenses as the Company submitted an NDA for Firdapse for the treatment of LEMS, as well as expenses from Catalyst's ongoing clinical trials and studies and its Expanded Access Program. The Company expects that costs related to research and development activities will continue to be substantial throughout 2019 as it continues its on-going clinical trials and studies in MuSK-MG and SMA Type 3 and its Expanded Access Program for Firdapse.
Selling, general and administrative expenses for the third quarter of 2019 totaled $8,067,792 as compared to $3,644,234 in the third quarter of 2018. For the nine months ended September 30, 2019, selling, general and administrative expenses were $25,471,974 as compared to $8,949,663 in the same period in 2018. The increase when compared to the same period in 2018 is primarily due to increased selling expenses, including costs of commercial system implementation, expansion of the Company's sales force and supporting personnel, product launch expenses, market access and market research expenses, and professional fees associated with Catalyst’s lawsuit against the FDA. The Company expects selling, general and administrative expenses to increase in 2019 and into 2020, as the Company continues to build its infrastructure and commercial and patient programs in support of Firdapse sales activities and pursues its lawsuit against the FDA.
At September 30, 2019, Catalyst had cash and cash equivalents and investments of $81.6 million and no funded debt. Catalyst believes that its existing capital resources will be sufficient to support its planned operations for at least the next 12 months.
More detailed financial information and analysis may be found in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission (SEC) on November 12, 2019.
Catalyst management will host an investment-community conference call and webcast at 8:30 a.m. ET, tomorrow, Wednesday, November 13, 2019 to discuss the financial results and provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States as a treatment for adults (age 17 and up) with LEMS.
Firdapse is being evaluated in clinical trials for the treatment of MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether the Company's forecast for net revenue in full year 2019 and full year 2020 will prove correct, (ii) whether Catalyst can successfully increase sales of Firdapse through expansion of its sales personnel from current levels, (iii) whether, even if Catalyst achieves its forecasted net revenue targets, it will remain profitable, (iv) whether Catalyst will be able to compete successfully for adult LEMS patients against off-label use of Ruzurgi® (which is priced lower than Firdapse), (v) whether payors will, in the future, require that patients try off-label Ruzurgi® first before such payors will approve Firdapse as a treatment for adult LEMS patients (vi) whether Catalyst’s NDS for Firdapse filed with Health Canada will be accepted for filing, and even if it is accepted for filing, whether it will be approved; (vii) whether Firdapse will ever be approved for the treatment of CMS, MuSK-MG, SMA Type 3, or any other disease, and (viii) those other factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2018 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. While Catalyst may voluntarily do so from time to time, Catalyst undertakes no commitment to update forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.
CATALYST PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
For the Three Months
Ended September 30,
For the Nine Months
Ended September 30,
|Product revenue, net.||$||30,897,444||$||--||$||72,183,782||$||--|
|Operating costs and expenses:|
|Cost of sales||4,387,461||--||10,360,874||--|
|Research and development||4,597,039||4,538,369||12,534,362||11,502,235|
|Selling, general and administrative||8,067,792||3,644,234||25,471,974||8,949,663|
|Total operating costs and expenses||17,052,292||8,182,603||48,367,210||20,451,898|
|Operating income (loss)||13,845,152||(8,182,603||)||23,816,572||(20,451,898||)|
|Other income, net||393,415||343,730||1,187,091||947,993|
|Net income (loss) before income taxes||14,238,567||(7,838,873||)||25,003,663||(19,503,905||)|
|Provision for income taxes||608,388||--||1,058,039||--|
|Net income (loss)||$||13,630,179||$||(7,838,873||)||$||23,945,624||$||(19,503,905||)|
|Net income (loss) per share:|
|Weighted average shares outstanding:|
CATALYST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
|Cash and cash equivalents||$||44,983,218||$||16,559,400|
|Accounts receivable, net||10,095,352||--|
|Prepaid expenses and other current assets||3,339,399||1,649,781|
|Total current assets||90,579,443||55,187,406|
|Operating lease right-of-use asset||952,340||--|
|Property and equipment, net||141,088||245,425|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued expenses and other liabilities||13,835,292||7,173,987|
|Total current liabilities||17,982,321||9,511,354|
|Accrued expenses and other liabilities, non-current||--||154,799|
|Operating lease liability, net of current portion||725,700||--|
|Total stockholders’ equity||77,982,538||50,783,809|
|Total liabilities and stockholders’ equity||$||96,690,559||$||60,449,962|
Investor Contact Brian Korb Solebury Trout (646) 378-2923 email@example.com Media Contact David Schull Russo Partners (212) 845-4271 firstname.lastname@example.org Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 email@example.com